The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

UnitedHealth Group (NYSE:UNH), a leading diversified healthcare company with a substantial market capitalization of $469.7 ...

Insurer-pharmacy benefit manager (PBM) firms control most of the Medicare Part D market, steering patients to their ...

UnitedHealth Q4 earnings beat EPS estimates at $6.81 but missed revenue projections. Analysts highlight growth potential in ...

As government scrutiny and enforcement targeting the Medicare Advantage (Medicare Part C) program continued in 2024, the ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

Analyst Joanna Gajuk of Bank of America Securities maintained a Buy rating on UnitedHealth (UNH – Research Report), reducing the price target ...

The Department of Justice (DOJ) recouped more than $2.9 billion for the federal government from False Claims Act settlements ...

Mizuho Securities analyst Ann Hynes has assigned their bullish stance on UNH stock, giving a Buy rating on January 15.Stay Ahead of the ...

This value-based world in which we find ourselves living presents a fascinating paradox. At the same time that it promises to ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story UnitedHealth CEO blames drug companies ...

UnitedHealth's CEO acknowledged discontent with the health care system, but quickly shifted the blame elsewhere.